Nightingale Health awarded “Health Innovation” of the Year
Nightingale Health’s pioneering blood testing service technology has been recognized as “Health Innovation” of the year by the Health Awards 2018. The Health Awards & Foresight Forum is an annual event focusing on the future vision of Finnish healthcare. Nightingale will allocate its €5,000 prize money towards a planned science magazine for children, equipping the next generation of budding innovators with a passion for medicine, science and technology.
"We believe that our technology will provide better tools for the prevention of chronic diseases in primary care. Solving the prevailing issues in healthcare today, requires the development of cutting-edge innovations and the courage to take advantage of the possibilities they bring. We are honored to receive this award and industry support, as we continue to make strides towards bringing our service to healthcare systems globally,” said Teemu Suna, CEO and Founder, Nightingale Health.
Nightingale’s service currently provides health data from biomarker analysis to leading academic research institutions and plans to assist clinicians in the near future to provide more personalized guidance to patients. In the long-term, Nightingale plans to fully integrate its service into healthcare systems and provide tools for patients to follow-up their own health – enabling preventative healthcare for chronic diseases (e.g. diabetes and cardiovascular disease). In March 2017, Nightingale was selected as one of the winners of MIT’s (Massachusetts's Institute of Technology) Solve competition, hosted at the United Nations HQ. In November 2017, Nightingale was awarded as one of the most innovative biotech SMEs in Europe at the European Parliament.
The Health Awards & Foresight Forum is a recognized competition and event carried out by the Tamro Corporation and partners in the Finnish health industry. The event brings together contributors, decision makers, companies and innovators in the healthcare and wellbeing sector.
Teemu Suna, CEO, Founder & Chairman
+358 40 196 1669
Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.6 trillion dollars annually. Our pioneering precision medicine services, include: effective chronic disease screening, health diagnostics and improving treatment efficacy. By providing our customers with accurate health data, we plan to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy.